Evaluation of clinical benefits of abiraterone acetate in "real life" study

Submission date	Recruitment status No longer recruiting	Prospectively registered	
30/04/2016		Protocol	
Registration date	Overall study status	Statistical analysis plan	
23/05/2016	Completed	[X] Results	
Last Edited	Condition category	[] Individual participant data	
18/02/2022	Cancer		

Plain English summary of protocol

Background and study aims

Prostate cancer is a very common cancer affecting men. The prostate is a small gland in the pelvis. It is found only in men and is usually the size of a satsuma. Its function is to help with the production of semen, producing a thick white fluid to be mixed with sperm. Cancer of the prostate usually develops slowly, so patients may not be aware that they have the disease for many years. In some cases, the cancer is only diagnosed at a later stage, when the disease has already spread (and called metastatic prostate cancer). Symptoms include needing to urinate more frequently than before, needing to rush to the toilet, having problems passing urine, and feeling that the bladder is not completely empty after urinating. In advanced cases, the cancer may spread to the bones and lymph nodes and, more rarely, the lungs and the liver. Treatment options include radiotherapy, hormone therapy, chemotherapy and partial or complete removal of the prostate. Testosterone usually makes the cancer grow more quickly so treatments can be given to stop the body producing so much of this hormone. In some cases, the part of the testicle that produces the testosterone is removed. After a time, these treatments can stop working, at which point the cancer is known as castration resistant prostate cancer. Studies have shown that a treatment called abiraterone acetate (AA) can improve survival for men with metastatic castration-resistant prostate cancer. This study aims to gain a better understanding regarding the use of this drug in clinical practice.

Who can participate?

Men diagnosed with metastatic prostate cancer, treated with AA.

What does the study involve?

Patients are treated with 1000mg of AA once a day and 5mg prednisone twice a day. This treatment continues until the disease progresses, the participant dies or the treatment becomes too toxic to take any more.

What are the possible benefits and risks of participating? Participants may benefit from taking part in this study though receiving a comprehensive, tailored follow-up.

Where is the study run from?
At least nine prostate cancer treatment centers in Italy

When is study starting and how long is it expected to run for? November 2015 to November 2016

Who is funding the study? Investigator initiated and funded

Who is the main contact? Dr Luca Cindolo

Contact information

Type(s)

Scientific

Contact name

Dr Luca Cindolo

ORCID ID

https://orcid.org/0000-0002-0712-2719

Contact details

Urology Department ASL Abruzzo 2 via S.Camillo de Lellis 1 Vasto Italy 66054

Additional identifiers

Protocol serial number

1.0

Study information

Scientific Title

Abiraterone acetate plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: multicentre Italian "real life" study

Study objectives

The aim of the study is to verify in clinical practice the results of RCTs concerning the abiraterone acetate in chemonaive patients wih metastatic castration-resistant prostate cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was waived by the departmental IRB.

Study design

Retrospective multicentre observational

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Metastatic castration resistant prostate cancer

Interventions

All patients enrolled were patients with an indication to receive abiraterone acetate (AA). All consecutive patients with biochemically or histologically confirmed progressive metastatic castration-resistant prostate cancer (mCRPC) and castrate levels of testosterone (<50 ng/dl.), chemonaive, treated with AA plus prednisone in 8 Italian tertiary cancer centres were gathered into a dedicated database. Patients were treated with AA 1000mg once daily in association with with prednisone 5mg twice a day until disease progression, death or unacceptable toxicity.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Abiraterone acetate

Primary outcome(s)

Progression free survival of patients enrolled (Overall Survival (OS), defined as time from the first dose of AA to the first clinical (pain, general status) or radiographic event), assessed from the time between treatment initiation to either the date of death or of last follow-up for surviving patients.

Key secondary outcome(s))

- 1. PSA changes measured at the baseline and at 12 weeks (the PSA decline was defined as a response at 12 wk equal or greater than 50% in PSA relative to baseline)
- 2. Toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 4.02 toxicity scale, assessed be evaluated monthly or earlier in case of toxic event
- 3. Dropout rate and the reasons for discontinuation, evaluated monthly or earlier in case of premature dropout
- 4. Patient's satisfaction about the treatment, using a 4-items specific questionnaire ("My condition has been: 1- greatly improved, 2- improved, 3- not changed, 4- worsened, during treatment"), evaluated every 12weeks or earlier in case of dropout

Completion date

30/11/2017

Eligibility

Key inclusion criteria

- 1. Men over the age of 18
- 2. Biochemically or histologically confirmed progressive mCRPC
- 3. Castrate levels of testosterone (<50 ng/dl)
- 4. Chemonaive
- 5. Eligible for abiraterone acetate

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Lower age limit

18 years

Sex

Male

Total final enrolment

145

Key exclusion criteria

Does not meet the inclusion criteria

Date of first enrolment

01/11/2015

Date of final enrolment

01/02/2016

Locations

Countries of recruitment

Italy

Study participating centre Urology Department

ASL Abruzzo 2 Chieti Italy 66100

Sponsor information

Organisation

Urology Department ASL Abruzzo 2

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

The dataset supporting the conclusions of this article is included as additional file to the results publication. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

IPD sharing plan summary

Available on request, Published as a supplement to the results publication

Study outputs

Output type	Details	Date created Date added	Peer reviewed	Patient-facing?
Results article	results	10/11/2017	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes